HEATT®

With two FDA Phase 1 clinical trials completed, Verthermia® intends to start clinical trials using HEATT® in early 2023 with additional funding. Research focused on the effectiveness of HEATT® on additional metastatic cancers, including pancreatic cancer, will be central to new therapies. If successful, new clinical treatments may extend life for patients who have exhausted their treatment options.

IMG_4525_edited.jpg

Research and Development

 

With additional funding, Verthermia will expand research on HEATT® and its effectiveness with other cancers. Furthermore, Verthermia® will continue to invest in the development of devices for the delivery of HEATT®.

Operation Theater